Nicholas Investment Partners’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Nicholas Investment Partners’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-19,388	Closed	-$2.8M	–	201
2020 Q1	$2.8M	Sell	19,388 -17,723	-48%	-$3.42M	0.54%	77
2019 Q4	$7.59M	Sell	37,111 -17,880	-33%	-$3.26M	0.78%	22
2019 Q3	$4.42M	Buy	54,991 +13,382	+32%	+$1.14M	0.37%	106
2019 Q2	$3.93M	Buy	41,609 +16,278	+64%	+$1.41M	0.36%	101
2019 Q1	$2.17M	Buy	+25,331	New	+$2.1M	0.19%	164

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nicholas Investment Partners's RETA Position: Q2 2020 in Review

Nicholas Investment Partners sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2020, closing a stake of 19,388 shares — an estimated $2.8M sold.

Nicholas Investment Partners first reported a position in RETA in Q1 2019 and held it in 5 quarters. The position peaked at $7.59M in Q4 2019. 207 funds tracked by Wall St. Rank hold RETA as of Q2 2020.

Nicholas Investment Partners reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2020 after selling out during the quarter.
Nicholas Investment Partners sold 19,388 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2020, an estimated $2.8M.
Nicholas Investment Partners first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 5 quarters.
Nicholas Investment Partners's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $7.59M in Q4 2019.
207 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2020.

Based on Nicholas Investment Partners's 13F filing for Q2 2020, filed 12 Aug 2020.